22nd Century EBIT Margin 2011-2023 | XXII
Current and historical EBIT (Earnings Before Interest & Taxes) margin for 22nd Century (XXII) over the last 10 years. The current EBIT profit margin for 22nd Century as of December 31, 2023 is .
| 22nd Century EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$0.03B |
$-0.04B |
-137.50% |
| 2023-09-30 |
$0.06B |
$-0.11B |
-177.05% |
| 2023-06-30 |
$0.06B |
$-0.05B |
-83.87% |
| 2023-03-31 |
$0.05B |
$-0.04B |
-81.13% |
| 2022-12-31 |
$0.04B |
$-0.03B |
-82.50% |
| 2022-09-30 |
$0.05B |
$-0.04B |
-84.00% |
| 2022-06-30 |
$0.04B |
$-0.04B |
-89.74% |
| 2022-03-31 |
$0.03B |
$-0.03B |
-96.97% |
| 2021-12-31 |
$0.03B |
$-0.03B |
-93.55% |
| 2021-09-30 |
$0.03B |
$-0.03B |
-86.67% |
| 2021-06-30 |
$0.03B |
$-0.02B |
-75.86% |
| 2021-03-31 |
$0.03B |
$-0.02B |
-74.07% |
| 2020-12-31 |
$0.03B |
$-0.02B |
-70.37% |
| 2020-09-30 |
$0.03B |
$-0.02B |
-70.37% |
| 2020-06-30 |
$0.03B |
$-0.02B |
-88.46% |
| 2020-03-31 |
$0.03B |
$-0.02B |
-88.46% |
| 2019-12-31 |
$0.03B |
$-0.02B |
-96.00% |
| 2019-09-30 |
$0.03B |
$-0.02B |
-96.00% |
| 2019-06-30 |
$0.03B |
$-0.02B |
-88.00% |
| 2019-03-31 |
$0.03B |
$-0.02B |
-92.31% |
| 2018-12-31 |
$0.03B |
$-0.02B |
-92.31% |
| 2018-09-30 |
$0.03B |
$-0.02B |
-88.00% |
| 2018-06-30 |
$0.02B |
$-0.02B |
-79.17% |
| 2018-03-31 |
$0.02B |
$-0.02B |
-71.43% |
| 2017-12-31 |
$0.02B |
$-0.01B |
-76.47% |
| 2017-09-30 |
$0.01B |
$-0.01B |
-85.71% |
| 2017-06-30 |
$0.01B |
$-0.01B |
-100.00% |
| 2017-03-31 |
$0.01B |
$-0.01B |
-109.09% |
| 2016-12-31 |
$0.01B |
$-0.01B |
-100.00% |
| 2016-09-30 |
$0.01B |
$-0.01B |
-100.00% |
| 2016-06-30 |
$0.01B |
$-0.01B |
-100.00% |
| 2016-03-31 |
$0.01B |
$-0.01B |
-100.00% |
| 2015-12-31 |
$0.01B |
$-0.01B |
-133.33% |
| 2015-09-30 |
$0.01B |
$-0.02B |
-250.00% |
| 2015-06-30 |
$0.00B |
$-0.02B |
-500.00% |
| 2015-03-31 |
$0.00B |
$-0.02B |
-1500.00% |
| 2014-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2014-09-30 |
$0.01B |
0 |
0.00% |
| 2014-06-30 |
$0.01B |
$0.00B |
28.57% |
| 2013-09-30 |
$0.00B |
$-0.01B |
inf% |
| 2012-09-30 |
$0.00B |
$-0.00B |
inf% |
| 2011-12-31 |
$0.00B |
$-0.00B |
-400.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.006B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
